Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Sclerosis – Access & Reimbursement – Access & Reimbursement – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market continues to evolve as each new approved disease-modifying therapy (DMT) further expands treatment choice. The most recent launches have entered…
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
Parkinson’s Disease – Unmet Need – Unmet Need – Levodopa-Induced Dyskinesia (US/EU)
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…
Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (EU5)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most…
Epilepsy – Current Treatment – Current Treatment: Physician Insights – Lennox-Gastaut Syndrome (US)
Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delays or regression, multiple seizure types, and electroencephalographic abnormalities…
Alzheimer’s Disease – Geographic Focus: China – Alzheimer’s Disease | China In-Depth | China | 2024
Market outlookAlzheimer’s disease (AD) is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing patients’ quality of life to…
